As a potent PDGFR inhibitor, STI-571 has been shown to inhibit breast cancer bone metastasis in mouse models [50], and it is being tested clinically in treatment of metastatic breast cancer, among other cancer types [51]. Here, PDGFRB is linked to breast carcinoma.